Atyr PHARMA (NASDAQ:ATYR - Get Free Report) issued its earnings results on Thursday. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05, Zacks reports.
Atyr PHARMA Stock Performance
NASDAQ ATYR traded down $0.02 on Friday, reaching $3.97. 2,401,773 shares of the stock were exchanged, compared to its average volume of 1,313,086. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. Atyr PHARMA has a one year low of $1.42 and a one year high of $4.66. The company's 50-day simple moving average is $3.65 and its two-hundred day simple moving average is $3.07. The firm has a market capitalization of $333.25 million, a PE ratio of -4.22 and a beta of 0.98.
Analysts Set New Price Targets
Several analysts have recently commented on ATYR shares. Leerink Partnrs upgraded shares of Atyr PHARMA to a "strong-buy" rating in a report on Tuesday, February 18th. Leerink Partners began coverage on shares of Atyr PHARMA in a research report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 target price for the company. Cantor Fitzgerald started coverage on shares of Atyr PHARMA in a research report on Monday, January 6th. They issued an "overweight" rating for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $35.00 target price on shares of Atyr PHARMA in a research report on Friday. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $18.60.
Check Out Our Latest Stock Report on ATYR
Atyr PHARMA Company Profile
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Recommended Stories
Before you consider Atyr PHARMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atyr PHARMA wasn't on the list.
While Atyr PHARMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
